Jason David Meade, DO | |
7050 N Recreation Ave Ste 105, Fresno, CA 93720-8001 | |
(559) 321-3001 | |
Not Available |
Full Name | Jason David Meade |
---|---|
Gender | Male |
Speciality | Urology |
Experience | 13 Years |
Location | 7050 N Recreation Ave Ste 105, Fresno, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538597356 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2088F0040X | Urology - Female Pelvic Medicine And Reconstructive Surgery | 20A15572 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Community Regional Medical Center | Fresno, CA | Hospital |
Fresno Surgical Hospital | Fresno, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Community Foundation Medical Group | 0345406294 | 263 |
News Archive
Freedom Meditech, Inc., the developer of non-invasive, ophthalmic-based products to detect and manage diabetes, today announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose measurements in the eye in a live animal model.
The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
Researchers at the Stanford University School of Medicine have illuminated the path taken by human neural stem cells that were transplanted into the brains of rats and mice, and found that the cells successfully navigate toward areas damaged by stroke.
› Verified 4 days ago
Entity Name | Community Foundation Medical Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811258510 PECOS PAC ID: 0345406294 Enrollment ID: O20120723000387 |
News Archive
Freedom Meditech, Inc., the developer of non-invasive, ophthalmic-based products to detect and manage diabetes, today announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose measurements in the eye in a live animal model.
The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
Researchers at the Stanford University School of Medicine have illuminated the path taken by human neural stem cells that were transplanted into the brains of rats and mice, and found that the cells successfully navigate toward areas damaged by stroke.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Jason David Meade, DO 7050 N Recreation Ave Ste 105, Fresno, CA 93720-8001 Ph: (559) 321-2930 | Jason David Meade, DO 7050 N Recreation Ave Ste 105, Fresno, CA 93720-8001 Ph: (559) 321-3001 |
News Archive
Freedom Meditech, Inc., the developer of non-invasive, ophthalmic-based products to detect and manage diabetes, today announced results of a clinical study that showed a high correlation between low to high blood glucose levels and non-invasive glucose measurements in the eye in a live animal model.
The U.S. Food and Drug Administration today announced that the manufacturers of Humira, Cimzia, Enbrel, and Remicade must strengthen the existing warnings, in the Warnings and Precaution sections of the drugs' prescribing information and Medication Guides, on the risk of developing opportunistic fungal infections. Some patients with invasive fungal infections have died.
Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA's Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar's efficacy and safety in the proposed patient population.
Researchers at the Stanford University School of Medicine have illuminated the path taken by human neural stem cells that were transplanted into the brains of rats and mice, and found that the cells successfully navigate toward areas damaged by stroke.
› Verified 4 days ago
Alice K Tsao, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Oak 2, Fresno, CA 93720 Phone: 559-448-4407 | |
Berhane Mebratu, NP Urology Medicare: Medicare Enrolled Practice Location: 7014 N Whitney Ave, Fresno, CA 93720 Phone: 559-321-2800 Fax: 559-321-2780 | |
Dr. Yuk-yuen Max Leung, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7014 N Whitney Ave, Ste A, Fresno, CA 93720 Phone: 559-321-2800 Fax: 559-321-2780 | |
Dr. Narayana Sriman Ambati, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7014 N Whitney Ave, Ste A, Fresno, CA 93720 Phone: 559-321-2858 Fax: 559-321-2780 | |
Dr. Artin Y Jibilian, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 255 N. Howard, Fresno, CA 93701 Phone: 559-459-7300 Fax: 559-459-3750 | |
Dr. Kuldip J.b.s. Behniwal, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 7014 N Whitney Ave, Ste A, Fresno, CA 93720 Phone: 559-321-2858 Fax: 559-321-2780 | |
Dr. Nedra Yvonne Hood, MD Urology Medicare: Medicare Enrolled Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4900 |